CN1969912A - Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof - Google Patents
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof Download PDFInfo
- Publication number
- CN1969912A CN1969912A CN 200510115021 CN200510115021A CN1969912A CN 1969912 A CN1969912 A CN 1969912A CN 200510115021 CN200510115021 CN 200510115021 CN 200510115021 A CN200510115021 A CN 200510115021A CN 1969912 A CN1969912 A CN 1969912A
- Authority
- CN
- China
- Prior art keywords
- dipyridamole
- herba erigerontis
- total flavones
- injection
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 27
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 24
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 238000003908 quality control method Methods 0.000 title claims abstract description 7
- 229930003944 flavone Natural products 0.000 claims abstract description 95
- 150000002213 flavones Chemical class 0.000 claims abstract description 95
- 235000011949 flavones Nutrition 0.000 claims abstract description 95
- 229960002768 dipyridamole Drugs 0.000 claims abstract description 92
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims abstract description 82
- 238000002347 injection Methods 0.000 claims abstract description 49
- 239000007924 injection Substances 0.000 claims abstract description 49
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 6
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 4
- 239000002131 composite material Substances 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims abstract description 3
- 201000006306 Cor pulmonale Diseases 0.000 claims abstract description 3
- 206010019468 Hemiplegia Diseases 0.000 claims abstract description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims abstract description 3
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 3
- 201000011200 hepatorenal syndrome Diseases 0.000 claims abstract description 3
- 206010047470 viral myocarditis Diseases 0.000 claims abstract description 3
- 238000010792 warming Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000006187 pill Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 11
- 239000007919 dispersible tablet Substances 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims description 4
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000001647 drug administration Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000007639 printing Methods 0.000 claims description 4
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims description 4
- 229930190376 scutellarin Natural products 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000000287 crude extract Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 2
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 238000004886 process control Methods 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 208000031225 myocardial ischemia Diseases 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 3
- 241000132521 Erigeron Species 0.000 description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 3
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 3
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- -1 polyoxyethylene monostearate Polymers 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241001013934 Erigeron breviscapus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Dipyridamole and significant parts of herba erigerontis flavones are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating cerebral thrombus, cerebral infarction, cerebral hemorrhage, hemiplegia, senile dementia, angina pectoris caused by coronary disease, myocardial infarction, auricular fibrillation, viral myocarditis, pulmonary heart disease, retina venous clogging, hepatorenal syndrome, diabetes and complications. The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved treatment effect, wider range of safely, and less fluctuation of treatment effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof and quality control method, belong to technical field of medicaments.
Technical background
Cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, apoplexy etc. have become one of key factor that threatens human health.According to investigations, sickness rate constantly increases in recent years, and continuous rejuvenation trend is arranged, in, young patient constantly increases, cardiovascular and cerebrovascular disease has become commonly encountered diseases, the frequently-occurring disease of harm China people ' s health.And at present medicine mainly concentrates on pure Chinese medicinal preparation and Western medicine two aspects, although the prescription of Western medicine is fairly simple, can very fast relief of symptoms, and owing to have certain toxic and side effects, be not suitable for long term administration, it is relatively poor to consolidate curative effect simultaneously; Though the pure Chinese medicinal preparation toxic and side effects is little, but their onset is slow, although some ejection preparations are widely used in the treatment of urgency, serious symptom, also obtain simultaneously certain curative effect, but because quality of the pharmaceutical preparations problem often influences therapeutic effect, though and oral preparation of Chinese traditional medicinal is various in style, indication is also more complete, but because bioavailability is not high, makes troubles for the part patient; Therefore in conjunction with the organic conception of Chinese medicine with consolidate principle and disease characteristics, carry out Chinese medicine and western medicine and be combined into the direction that people begin one's study.Lot of documents report, Herba Erigerontis total flavones have antithrombotic and form, and anticoagulant resists myocardial ischemia, and is mainly used in obliterated cerebral vascular disease clinically, the treatment of cardiovascular and cerebrovascular disease such as paralyse after coronary heart disease, angina pectoris, vasculitis, the apoplexy; Dipyridamole has anticoagulant, effects such as antithrombotic formation, be widely used in the treatment of cardiovascular and cerebrovascular diseases such as myocardial ischemia, angina pectoris, cerebral thrombosis, clinical discovery, fleabane preparation such as Herba Erigerontis injection determined curative effect, but existing preparation common oral preparation bioavailability is low, and day clothes number of times is more, the normal injection preparation administration half-life is short, eliminate in the body rapidly, curative effect has certain undulatory property simultaneously, and dipyridamole is unsuitable for taking for a long time because untoward reaction is arranged; In view of such circumstances, searching better, compatibility is simple, therapeutic effect is desirable, and effective medicine that toxic and side effects is little has just become people's urgent problem.
Summary of the invention
The objective of the invention is to: a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is provided, this pharmaceutical composition is by dipyridamole and Herba Erigerontis total flavones effective site prescription, definite ingredients, quality controllable, can anticoagulant, again can replenishing qi and promoting blood flow, treating both the principal and secondary aspects of a disease, produce obvious synergism, curative effect obviously improves; The present invention also aims to provide the preparation method and the quality control method of this pharmaceutical composition different dosage form; At prior art, according to cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all contract because of blood vessel is narrow, reason such as blood flow minimizing, blood stasis causes the diseases induced principle of blood supply insufficiency, on the basis of experiment screening, adopt dipyridamole and Herba Erigerontis total flavones compatibility to make preparation, optimize best prescription and technology, the product that obtains, show through pharmacodynamics test, Synergistic, more independent fleabane preparation, the dipyridamole formulation curative effect all is significantly increased.
The technical solution adopted in the present invention is:
A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease calculates according to parts by weight, and it is mainly to be made for 0.01～50 part by 1 part of dipyridamole and Herba Erigerontis total flavones.Specifically, calculate according to parts by weight, it is mainly to be made for 0.1～10 part by 1 part of dipyridamole and Herba Erigerontis total flavones.Preferred prescription is: calculate according to parts by weight, it is mainly to be made for 1～5 part by 1 part of dipyridamole and Herba Erigerontis total flavones.
Described combination dosage form be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution all acceptable dosage forms on the pharmaceuticss such as the concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet, dispersible tablet, membrane, sublingual lozenge.Preferred dosage form comprise the injection that is directly used in drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and drop pill, pellet, oral liquid, oral cavity disintegration tablet, dispersible tablet, sublingual lozenge.
Described composite preparation can make on the basis that in Herba Erigerontis total flavones and the dipyridamole one or both is prepared into liposome or pro-liposome.
Herba Erigerontis total flavones effective site is commercially available or adopts following method to prepare in the present composition: get the Herba Erigerontis medical material, adding entry or alcoholic solution extracts, merge extractive liquid,, filter, filtrate concentrate the Herba Erigerontis crude extract, adopt on this basis ethanol precipitation, water return in molten method, column chromatography, extraction, the flocculent precipitation one or more unite use carry out suitably refining, Herba Erigerontis total flavones effective site.
Calculate by weight percentage, the content of flavones ingredient is not less than in the preparation 50% of total solid after deduction dipyridamole amount, pharmaceutical adjunct amount and the water quantities in the oral formulations, and the content of flavones ingredient is not less than 70% of total solid after deduction dipyridamole amount, pharmaceutical adjunct amount and the water quantities in the ejection preparation; Dipyridamole content should be 90.0%～110.0% of preparation labelled amount.
The Injectable sterile block prepares like this: get dipyridamole, add the stirring of 0.5% tartaric acid or citric acid and make it dissolving; Get Herba Erigerontis total flavones and add injection and blunge and make dissolving, two solution are mixed shaking up, filter, filtrate is boiled the active carbon that the back adds 0.5% (W/V), keep little and boiled 30 minutes, cold slightly filtration, filtrate adjust pH to 6.5～8.0, boil, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; Be warming up to-35 ℃ again, keep 8h; Be warming up to-25 ℃, keep 8h; Be warming up to-15 ℃, keep 5h; Be warming up to 0 ℃, keep 5h; Be warming up to 10 ℃, keep 2h; Be warming up to 20 ℃, keep 2h; Be warming up to 30 ℃, keep 2h promptly.
The present composition is mainly used in treatment cerebral thrombosis, cerebral infarction, cerebral hemorrhage, post-stroke hemiplegia, diseases such as alzheimer disease, angina pectoris, myocardial infarction, atrial fibrillation, viral myocarditis, pulmonary heart disease, the retinal vein occlusion, hepatorenal syndrome, diabetes and complication thereof.
The method of quality control of the pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease comprises following all or part of content:
(1) finger printing test comprises with the Herba Erigerontis flavones ingredient being characterized as main finger printing;
(2) all or part of differential test method in Herba Erigerontis medical material, scutellarin, the dipyridamole etc.;
(3) content test method of all or part of composition in scutellarin, total flavones, the dipyridamole etc.
Compared with prior art, pharmaceutical composition of the present invention is by dipyridamole and Herba Erigerontis total flavones effective site prescription, the Herba Erigerontis flavones ingredient has tangible antithrombotic and forms, and anticoagulant resists myocardial ischemia, effects such as blood vessel dilating, blood viscosity lowering, microcirculation improvement; But dipyridamole anticoagulant, have effects such as antithrombotic formation, the two all is widely used in the treatment of cardiovascular and cerebrovascular disease, Herba Erigerontis total flavones and dipyridamole prescription, purity height, definite ingredients, quality controllable, it is big to have overcome the fluctuation of pure Chinese medicinal preparation curative effect simultaneously, the shortcoming that the Western medicine untoward reaction is many, can guarantee the stable and drug safety of clinical efficacy, Integrative Chinese-Western, treating both the principal and secondary aspects of a disease, the Synergistic attenuation all is significantly improved with fleabane preparation or dipyridamole formulation curative effect than single.
For proving that medicine provided by the invention has effective effect, the applicant has carried out a series of experiments.
Experimental example 1: to the comparative study of different proportioning pharmacodynamics
1, myocardial infarction and ischemia model test due to the medicine method
90 of healthy SD rats, body weight 200～250g, the male and female dual-purpose, be divided into 9 groups, grouping sees the following form, every group 10, male and female half and half, give relative medicine shown in the according to the form below, continuous 7 days, after the last administration 1 hour, through with sodium pentobarbital 30mg/kg intravenous anesthesia, one section normal II ECG that leads was write down with the safe BL-420 of alliance type biological function signaling system in fixing back, back of the body position, iv pituitrin 1ug/kg then, 15s after administration, 30s, 1min, 2min, 3min, 4min, 5min, 10min, 15min, 20min writes down the II ECG that leads respectively, and with the T ripple of any time wherein or ST section rising 0.1mv or decline 0.05mv as the positive number of animals of myocardial ischemia, the results are shown in Table 1.
Table 1 pair rat pituitary pituitrin brings out the influence of acute myocardial ischemia
| Group | Mus number (only) | The positive number of animals (only) of myocardial ischemia |
| 0.1: 1 Herba Erigerontis total flavones of 1: 1 Herba Erigerontis total flavones of 5: 1 Herba Erigerontis total flavones of 10: 1 Herba Erigerontis total flavones of 50: 1 Herba Erigerontis total flavones of physiological saline group dipyridamole injection liquid group Erigeron Breviscapus Injection group Herba Erigerontis total flavones-Dipyridamole group-Dipyridamole group-Dipyridamole group-Dipyridamole group-Dipyridamole group-Dipyridamole group 0.01: 1 | 10 10 10 10 10 10 10 10 10 | 10 7 6 5 5 2 1 4 3 |
As shown in Table 1, the medicine of Herba Erigerontis total flavones and the different proportionings of dipyridamole can obviously resist the myocardial ischemia due to the pituitrin, the strong and weak degree of this effect is relevant with the proportioning of medicine, and wherein with Herba Erigerontis total flavones: dipyridamole is that 1～5: 1 prescription pharmacological action is strong and consumption is lower.
2, to the influence of rabbit platelet aggregation
Get 45 of rabbit, body weight 3～5kg, male, be divided into 9 groups, grouping sees the following form, 5 every group, give relative medicine shown in the according to the form below, measure surface activity of blood platelet and aggregation from heart extracting blood before the administration, in auricular vein injection relative medicine or equivalent normal saline, check surface activity of blood platelet or aggregation after 1 hour.The results are shown in Table 2.
The influence of table 2 pair platelet aggregation
| Group | Circle tree type (%) | Expansion type (%) | Aggregation number (individual) | |||
| Before the administration | After the administration | Before the administration | After the administration | Before the administration | After the administration | |
| 0.1: 1 Herba Erigerontis total flavones of 1: 1 Herba Erigerontis total flavones of 5: 1 Herba Erigerontis total flavones of 10: 1 Herba Erigerontis total flavones of 50: 1 Herba Erigerontis total flavones of physiological saline group dipyridamole injection liquid group Erigeron Breviscapus Injection group Herba Erigerontis total flavones-Dipyridamole group-Dipyridamole group-Dipyridamole group-Dipyridamole group-Dipyridamole group-Dipyridamole group 0.01: 1 | 71.5± 2.15 72.3± 5.17 71.6± 5.92 70.8± 5.68 69.8± 5.38 71.6± 6.05 70.4± 5.28 69.5± 6.15 68.7± 5.28 | 73.6± 2.57 79.8± 5.31 76.4± 5.27 79.5± 5.89 83.1± 5.42 89.5± 7.58 88.2± 5.63 83.6± 5.78 76.9± 6.29 | 28.5± 2.15 27.7± 5.17 28.4± 5.92 29.2± 5.68 30.2± 5.38 28.4± 6.05 29.6± 5.28 30.5± 6.15 31.3± 5.28 | 26.4± 2.57 20.2± 5.31 23.6± 5.27 20.5± 5.89 16.9± 5.42 10.5± 7.58 11.8± 5.63 21.8± 5.24 24.4± 4.75 | 65.8± 2.36 66.1± 4.89 64.2± 6.24 63.7± 5.17 64.8± 4.25 62.9± 5.23 60.4± 5.12 63.7± 3.58 60.5± 4.26 | 62.5± 2.78 57.6± 4.23 56.8± 4.35 50.4± 5.38 48.2± 4.57 43.5± 8.26 40.2± 7.48 47.2± 6.05 47.8± 5.22 |
As shown in Table 2, the medicine of Herba Erigerontis total flavones and the different proportionings of dipyridamole can significantly reduce surface activity of blood platelet or aggregation effect, and the strong and weak degree of this effect is relevant with the proportioning of medicine.
Table 1, table 2 show: Herba Erigerontis total flavones compatibility dipyridamole can produce synergistic function, drug effect all is significantly improved than singly using with dosage dipyridamole or Herba Erigerontis total flavones, the medicine of dipyridamole and the different proportionings of Herba Erigerontis total flavones all can significantly increase curative effect, but the strong and weak degree of effect is relevant with the proportioning of medicine; From interpretation, the best proportioning of Herba Erigerontis total flavones and dipyridamole is: 1 part of dipyridamole, 1～5 part of Herba Erigerontis total flavones.
Experimental example 2: injection Study on Forming
2.1pH value is to the influence of injection
For adapting to the Human Physiology needs, consider the character of each constituents in the medicinal liquid simultaneously, the applicant placed 3 months for 40 ℃ the injection of 8 kinds of different pH value, investigated its stability respectively.The results are shown in following table.
| PH value | 0 month | March | ||
| Clarity | Total flavones (mg/ml) | Clarity | Total phenolic acid (mg/ml) | |
| 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 | The difference difference is clear and bright clear and bright slightly poor | 0.85 0.85 0.85 0.85 0.85 0.85 0.85 0.85 | The difference difference is clear and bright clear and bright poor | 0.70 0.73 0.78 0.81 0.82 0.83 0.83 0.75 |
The result shows that the rational pH value scope of the present invention is 6.0～8.0.
2.2 activated carbon dosage influences injection
Injection has the pyrogen material owing to solvent, raw material, container etc. in process of production, and the safety of injection is reduced, and therefore needs to remove the pyrogen material in the process of preparation injection.The applicant adopts active carbon adsorption, and heat of adsorption originality composition helps filter and decolouring simultaneously on the one hand, also can improve the appearance character of preparation, because of active carbon is investigated its consumption.
The activated carbon dosage investigation table
| Activated carbon dosage (%) | The total flavones rate of transform (%) | Outward appearance |
| 0.1 0.5 1.0 | 70.5 68.2 63.7 | Reddish brown red |
As seen from table, the three all can satisfy the related request of injection, but from the medicinal liquid outward appearance, select activated carbon dosage be 0.5% and 1.0% proper; Judge that from the rate of transform 0.1% consumption and 0.5% consumption are slightly better, take all factors into consideration above factor, so that be good with the activated carbon decolorizing of medicine liquid volume 0.5%.
2.3 lyophilization conditional filtering
Lyophilization is a veryer long dry run, also is the process of a power consumption simultaneously.An ideal lyophilisation condition not only can make the samples met standard, simultaneously also can save the energy and man-hour, so we are optimized screening to lyophilisation condition, sees Table.
Table lyophilization conditional filtering
| Time-temperature (℃) | Condition I | Condition II | Condition III | Cold-trap |
| -45 (pre-freeze)-40 (pre-freeze)-40 (vacuumizing)-35 (vacuumizing)-25 (vacuumizing)-15 (vacuumizing) 0 (vacuumizing) 10 (vacuumizing), 20 (vacuumizing) 30 (vacuumizing) | 10 - 8 8 8 5 5 2 2 2 | - 8 - 8 8 8 5 4 4 4 | 10 - 10 10 10 5 5 9 2 2 | Keep-70 ℃ |
Experimental result shows: spray bottle, atrophy phenomenon, the finished product appearance character that condition I and condition III make and the equal conformance with standard of moisture appear in condition II gained sample.Consider the practical situation of production, the condition I that the finally selected overall time spent is short, i.e. lyophilization condition is: pre-freeze temperature-45 ℃, pre-freeze time 10h; The beginning evacuation, and be warming up to-40 ℃, keep 8h; Be warming up to-35 ℃ again, keep 8h; Be warming up to-25 ℃, keep 8h; Be warming up to-15 ℃, keep 5h; Be warming up to 0 ℃, keep 5h; Be warming up to 10 ℃, keep 2h; Be warming up to 20 ℃, keep 2h; Be warming up to 30 ℃, keep 2h, get finished product.
Experimental example 3: dispersible tablet disintegrating agent screening
The kind of disintegrating agent, quantity directly have influence on the dispersing uniformity of preparation in the dispersible tablet, are the leading indicators of weighing the dispersible tablet quality, thus we to select disintegration time for use be that performance assessment criteria is investigated different disintegrating agents, the results are shown in following table.
The disintegrating agent table of merit rating
| Disintegrating agent | With the ointment ratio | Disintegration time (minute) |
| Crospolyvinylpyrrolidone low-substituted hydroxypropyl cellulose carboxymethyl starch sodium crospolyvinylpyrrolidone, the low-substituted hydroxypropyl cellulose low-substituted hydroxypropyl cellulose, the microcrystalline Cellulose crospolyvinylpyrrolidone, microcrystalline Cellulose | 1∶3 1∶3 1∶3 1∶3 1∶3 1∶3 | 2.4 2.6 2.8 2.1 2.5 2.3 |
From the result of above-mentioned test as can be seen, most of disintegrating agent can improve the disintegration time of dispersible tablet, all can reach the requirement of dispersible tablet.But by contrast, after employing crospolyvinylpyrrolidone and the low-substituted hydroxypropyl cellulose combination, the disintegrate best results.
Test example 4: drop pill substrate screening
The inventor is prepared into the required substrate of drop pill to extract and investigates by a large amount of tests, and different etc. with fusion situation, the ball method of double differences of drop pill outward appearance, principal agent and substrate serves as to investigate index, optimizes and has screened the substrate that influence the drop pill quality, and result of the test is as showing.
Method: substrate is put in the small beaker, be heated to 80～90 ℃, after treating whole fusions, the mixed material that adds dipyridamole and Herba Erigerontis total flavones, investigate the fusion situation of substrate and material, (drip the system condition: expect 75 ℃ of temperature, coolant is a dimethicone to the system of dripping to select the fusion situation to write out a prescription preferably, drip apart from 3～7cm, drip 30～45 droplets/minute of speed).
Table substrate screening test
| Sequence number | 1 | 2 | 3 | 4 | 5 |
| It is different that heavy (g) PEG4000 PEG6000 polyoxyl 40 stearate polyethers poloxamer matrix of material and material merge the situation dripping pill outward appearance ball method of double differences | 20 40----better smooth, roundness slightly differs from 7.0% | 20 30-10--better smooth, roundness 6.5% | 20--10-30 relatively poor roundness differ from 8.2% | 20-30-10-better matter is soft, roundness 8.6% | 20-20--20 better matter are soft, roundness 7.2% |
From above table as can be seen, most of substrate can satisfy the needs of preparations shaping, but with the combination condition optimum of PEG4000 and polyoxyethylene monostearate.
Concrete embodiment
Embodiments of the invention 1: dipyridamole 10g Herba Erigerontis total flavones 50g
Get dipyridamole, add the stirring of 0.5% tartaric acid or citric acid and make it dissolving; Get Herba Erigerontis total flavones and add injection and blunge and make dissolving, two solution are mixed shaking up, filter, filtrate is boiled the needle-use activated carbon that the back adds 0.5% (W/V), keep little and boiled 30 minutes, cold slightly filtration, filtrate adjust pH to 6.5～8.0, boil, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; Be warming up to-35 ℃ again, keep 8h; Be warming up to-25 ℃, keep 8h; Be warming up to-15 ℃, keep 5h; Be warming up to 0 ℃, keep 5h; Be warming up to 10 ℃, keep 2h; Be warming up to 20 ℃, keep 2h; Be warming up to 30 ℃, keep 2h to get finished product.Promptly get the aseptic block of lyophilizing that contains 1 part of dipyridamole and 5 parts of Herba Erigerontis total flavones.
Embodiments of the invention 2: dipyridamole 1g Herba Erigerontis total flavones 1g
Get dipyridamole, add the stirring of 0.5% tartaric acid or citric acid and make it dissolving; Get Herba Erigerontis total flavones, add an amount of stirring of injection water and make it dissolving, two medicinal liquid mixings, adding 5mol/L sodium hydroxide solution adjusting pH value is 6.0～8.0, adds the activated needle-use activated carbon of 0.5% (W/V), boils absorption, carbon removal, fine straining, filtrate adds the injection water to ormal weight, spend the night 4 ℃ of cold preservations, coarse filtration, fine straining divide to install in the ampoule bottle sterilization, packing promptly gets the injection with small volume or the concentrated solution for injection that contain 1 part of dipyridamole and 1 part of Herba Erigerontis total flavones.
Embodiments of the invention 3: dipyridamole 10g Herba Erigerontis total flavones 500g
Get dipyridamole and add the injection water, add the stirring of 0.5% tartaric acid and make it dissolving, medicinal liquid is standby; Get Herba Erigerontis total flavones, add an amount of water for injection dissolving, medicinal liquid is standby; Above-mentioned two medicinal liquids are merged, add the glucose or the sodium chloride of ormal weight, by volume add 0.5% needle-use activated carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to an amount of, and boil adjust pH to 6.0～8.0,4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add to the full amount of water for injection, packing, sterilization promptly gets the glucose or the sodium chloride intravenous infusion that contain 1 part of dipyridamole and 50 parts of Herba Erigerontis total flavones.
Embodiments of the invention 4: dipyridamole 5g Herba Erigerontis total flavones 50g
Get dipyridamole and add the injection water, add the stirring of 0.2% citric acid and make it dissolving, medicinal liquid is standby; Get Herba Erigerontis total flavones, add an amount of water for injection, stir and make dissolving, medicinal liquid is standby; Above-mentioned two medicinal liquids are merged, adjust pH to 6.5～8.0 add the injection water to ormal weight, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, divide and install in the enamel tray, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 1.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-40 ℃, need 2 hours approximately, kept this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, under-40 ℃ of constant temperature-evacuation, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, time is about 12 hours, after sublimation drying is finished, continue under the low pressure condition, it is dry to remove residual moisture to heat up, time is about 14～16 hours, kept more than 35 ℃ dry 1.5 hours, and under aseptic condition, divided to install in the cillin bottle, promptly get the lyophilizing injectable sterile powder that contains 1 part of dipyridamole and 10 parts of Herba Erigerontis total flavones.
Embodiments of the invention 5: dipyridamole 100g Herba Erigerontis total flavones 1g
Getting dipyridamole, to add injection water and citric acid an amount of, stirs and make it dissolving, and medicinal liquid is standby; Get Herba Erigerontis total flavones, add an amount of water for injection dissolving, medicinal liquid is standby; Above-mentioned two medicinal liquids are merged, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to an amount of, boil adjust pH to 6.5～8.0, and 4 ℃ of cold preservations are spent the night, add to the full amount of water for injection, coarse filtration, fine straining are 180 ℃ in inlet temperature, leaving air temp is 50 ℃, air velocity is a spray drying under the condition of 18ms-1, and packing promptly gets and contains 1 part of dipyridamole and 0.01 part of Herba Erigerontis total flavones spray drying sterilized powder.
Embodiments of the invention 6: dipyridamole 10g Herba Erigerontis total flavones 1g
With dipyridamole and Herba Erigerontis total flavones mix homogeneously, polyvinylpyrrolidone, the stevioside of adding 8% are an amount of, and compacting promptly gets the oral cavity disintegration tablet that contains 1 part of dipyridamole and 0.1 part of Herba Erigerontis total flavones in flakes.
Embodiments of the invention 7: dipyridamole 10g Herba Erigerontis total flavones 30g
With dipyridamole 10g, Herba Erigerontis total flavones 30g, PEG4000 and polyoxyethylene monostearate (3: 1) 80g mix homogeneously, put in the rustless steel container mixing, after being heated to whole fusions, insulation 30min, mechanical high-speed stirs 10min to evenly, is transferred to the drop pill machine, with dimethicone or liquid paraffin is coolant, drip system, collect drop pill, remove the dimethicone or the liquid paraffin on surface, packing promptly gets the drop pill that contains 1 part of dipyridamole and 3 parts of Herba Erigerontis total flavones.
Embodiments of the invention 8: dipyridamole 6g Herba Erigerontis total flavones 30g
With dipyridamole and Herba Erigerontis total flavones mix homogeneously, in principal agent: the ratio of adjuvant=3: 1 adds crospolyvinylpyrrolidone and low-substituted hydroxypropyl cellulose composite auxiliary material mix homogeneously, the system soft material, granulate, dry, granulate, tabletting promptly gets and contains 1 part of dipyridamole and 5 parts of Herba Erigerontis total flavones dispersible tablets.
Embodiments of the invention 9: dipyridamole 3g Herba Erigerontis total flavones 21g
With dipyridamole and Herba Erigerontis total flavones mix homogeneously, add appropriate amount of starch, dextrin, to granulate, drying adds magnesium stearate, and coating promptly gets the tablet that contains 1 part of dipyridamole and 7 parts of Herba Erigerontis total flavones.
Embodiments of the invention 10: dipyridamole 50g Herba Erigerontis total flavones 0.5g
With dipyridamole 3g and Herba Erigerontis total flavones 24g mix homogeneously, add 3 times of amount starch and 1 times of amount dextrin, mix homogeneously is granulated, drying, granulate, encapsulated, promptly get the capsule that contains 1 part of dipyridamole and 0.01 part of Herba Erigerontis total flavones.
Embodiments of the invention 11: dipyridamole 2.5g Herba Erigerontis total flavones 5g
With dipyridamole and Herba Erigerontis total flavones mix homogeneously, add the vegetable oil of 0.5 times of weight and 1.2% Cera Flava, the dropping preparation method pill, compacting promptly gets and contains 1 part of dipyridamole and 0.5 part of Herba Erigerontis total flavones soft capsule.
Embodiments of the invention 12: dipyridamole 4g Herba Erigerontis total flavones 16g
With dipyridamole, Herba Erigerontis total flavones mixing, add medicinal starch, Celluloasun Microcrystallisatum is an amount of, mixing, the spheronization pill, packing promptly gets the pellet that contains 1 part of dipyridamole and 4 parts of Herba Erigerontis total flavones.
Embodiments of the invention 13: dipyridamole 2g Herba Erigerontis total flavones 8g
With Herba Erigerontis total flavones, dipyridamole mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, gets liposome turbid liquor, the phosphate buffer standardize solution, filtration sterilization, aseptic subpackaged, promptly get lipidosome injection.
Embodiments of the invention 14: dipyridamole 8g Herba Erigerontis total flavones 2g
With Herba Erigerontis total flavones, dipyridamole mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 8min, gets liposome turbid liquor, behind the frozen drying, cross 180 mesh sieves, aseptic subpackaged, promptly get the pro-liposome injectable powder.
Dipyridamole among the above embodiment is the commercial goods that can directly buy, Herba Erigerontis total flavones can be with commercially available or Herba Erigerontis alcohol extract provided by the invention, water extract, water extract-alcohol precipitation extract, semi-bionic extraction thing, supercritical extract or the like, but: the content for flavones ingredient in the oral Herba Erigerontis total flavones is not less than 50%, and the content of flavones ingredient is not less than 70% in the Herba Erigerontis total flavones of injection.
Claims (11)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that: calculate according to parts by weight, it is mainly to be made for 0.01～50 part by 1 part of dipyridamole and Herba Erigerontis total flavones.
2, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to parts by weight, it is mainly to be made for 0.1～10 part by 1 part of dipyridamole and Herba Erigerontis total flavones.
3, according to the pharmaceutical composition of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: calculate according to parts by weight, it is mainly to be made for 1～5 part by 1 part of dipyridamole and Herba Erigerontis total flavones.
4, pharmaceutical composition according to any described treatment cardiovascular and cerebrovascular disease of claim 1～3 is characterized in that: described combination dosage form is the injection that is directly used in drug administration by injection, directly supply the venous transfusion of intravenous drip, need to be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and the tablet that makes with freeze-drying or spray drying method after the dilution, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet, dispersible tablet, membrane, all acceptable dosage forms on the pharmaceuticss such as sublingual lozenge.
5, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that: described combination dosage form comprise the injection that is directly used in drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and drop pill, pellet, oral liquid, oral cavity disintegration tablet, dispersible tablet, sublingual lozenge.
6, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4～5, it is characterized in that: described composite preparation can make on the basis that in Herba Erigerontis total flavones and the dipyridamole one or both is prepared into liposome or pro-liposome.
7, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: Herba Erigerontis total flavones effective site is commercially available or adopts following method to prepare: get the Herba Erigerontis medical material, adding entry or alcoholic solution extracts, merge extractive liquid,, filter, filtrate concentrate the Herba Erigerontis crude extract, adopt on this basis ethanol precipitation, water return in molten method, column chromatography, extraction, the flocculent precipitation one or more unite use carry out suitably refining, Herba Erigerontis total flavones effective site.
8, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 4～6, it is characterized in that: calculate by weight percentage, the content of flavones ingredient is not less than in the preparation 50% of total solid after deduction dipyridamole amount, pharmaceutical adjunct amount and the water quantities in the oral formulations, and the content of flavones ingredient is not less than 70% of total solid after deduction dipyridamole amount, pharmaceutical adjunct amount and the water quantities in the ejection preparation; Dipyridamole content should be 90.0%～110.0% of preparation labelled amount.
9, according to the preparation of drug combination method of any described treatment cardiovascular and cerebrovascular disease in the claim 1～5, it is characterized in that: the Injectable sterile block prepares like this: get dipyridamole, add the stirring of 0.5% tartaric acid or citric acid and make it dissolving; Get Herba Erigerontis total flavones and add injection and blunge and make dissolving, two solution are mixed shaking up, filter, filtrate is boiled the needle-use activated carbon that the back adds 0.5% (W/V), keep little and boiled 30 minutes, cold slightly filtration, filtrate adjust pH to 6.5～8.0, boil, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; Be warming up to-35 ℃ again, keep 8h; Be warming up to-25 ℃, keep 8h; Be warming up to-15 ℃, keep 5h; Be warming up to 0 ℃, keep 5h; Be warming up to 10 ℃, keep 2h; Be warming up to 20 ℃, keep 2h; Be warming up to 30 ℃, keep 2h, promptly.
10, according to the application of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: described compositions is used for preparation treatment cerebral thrombosis, cerebral infarction, cerebral hemorrhage, post-stroke hemiplegia, disease medicaments such as alzheimer disease, angina pectoris, myocardial infarction, atrial fibrillation, viral myocarditis, pulmonary heart disease, the retinal vein occlusion, hepatorenal syndrome, diabetes and complication thereof.
11, according to the method for quality control of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 4～6, it is characterized in that: this method comprises following all or part of content:
(1) finger printing test comprises with the Herba Erigerontis flavones ingredient being characterized as main finger printing;
(2) all or part of differential test method in Herba Erigerontis medical material, scutellarin, the dipyridamole etc.;
(3) content test method of all or part of composition in scutellarin, total flavones, the dipyridamole etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115021 CN1969912A (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115021 CN1969912A (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1969912A true CN1969912A (en) | 2007-05-30 |
Family
ID=38111060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510115021 Pending CN1969912A (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1969912A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113713100A (en) * | 2013-07-29 | 2021-11-30 | 瑞采生技有限公司 | Methods for enhancing delivery of antiplatelet agents for the treatment of acute stroke and compositions thereof |
-
2005
- 2005-11-23 CN CN 200510115021 patent/CN1969912A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113713100A (en) * | 2013-07-29 | 2021-11-30 | 瑞采生技有限公司 | Methods for enhancing delivery of antiplatelet agents for the treatment of acute stroke and compositions thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1969912A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN100542548C (en) | A traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparation method | |
| CN1969927A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969911A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969967A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969939A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969977A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969950A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969978A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969899A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969902A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969908A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969917A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969897A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969900A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969966A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969949A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969916A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969926A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969906A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1981800A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1969907A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969920A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969898A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969919A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |